*All times are shown in EDT

7:30 am Online Networking Coffee

7:50 am Opening Remarks from Chairperson

Immunotherapy Strategy for NSCLC

8:00 am Independent Action, Collateral Sensitivity, & Directions For Future Progress For Immune Checkpoint Inhibitors in NSCLC

  • Emmett V. Schmidt Vice President, Clinical Research Lead, External Collaborations Oncology Early Development , Merck and Co

Synopsis

• What is old is still true: current approved immune checkpoint inhibitor combinations depend on combinations of orthogonal cancer therapies according to principles of independent activity
• The future is here: The emerging landscape of post-PD-1 treatment trials
• What is old is still true: A reminder of collateral sensitivity as a historic combination principle

8:30 am Is Now the Critical Tipping Point for Progress with Immunotherapy in Resectable NSCLC? Where Are We Now and What’s to Come in 2021 and Beyond?

  • Tony Jarkowski Executive Director, Early Development Program Lead, Bristol Myers- Squibb

Synopsis

  • Review historical data along with current approaches for potentially resectable NSCLC
  • Discuss drug development in NSCLC and why progress in resectable NSCLC has lagged behind advanced stages of disease
  • Describe emerging data, science, and future opportunities for immunotherapy to improve outcomes within resectable NSCLC, including the neoadjuvant, adjuvant and peri-adjuvant settings

9:00 am Speaker Q&A

  • Emmett V. Schmidt Vice President, Clinical Research Lead, External Collaborations Oncology Early Development , Merck and Co
  • Tony Jarkowski Executive Director, Early Development Program Lead, Bristol Myers- Squibb

9:10 am A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC

Synopsis

  • An MHC class II agonist (eftilagimod) used as an antigen presenting cell (APC) activator combined with an immune checkpoint inhibitor (ICI): a unique combination in immuno-oncology
  • Results in first and second (in PD-X refractory patients) lines non-small cell lung carcinoma (NSCLC)

9:40 am Reprogramming of the Lung Cancer Tumour Microenvironment with the AXL Inhibitor Bemcentinib.

  • Hani Gabra Chief Medical Officer & Head of Clinical Development , BerGenBio AS

10:10 am Speaker Q&A

  • Frederic Triebel Chief Scientific Officer & Chief Medical Officer , Immutep
  • Hani Gabra Chief Medical Officer & Head of Clinical Development , BerGenBio AS

10:20 am Morning Networking Coffee Break

Targeting Rare Mutations in NSCLC

11:00 am Targeting RAF Dimer Signaling in NSCLC Driven by BRAF Class II and III Mutations

  • Eric Murphy Co-Founder and Chief Scientific Officer , Kinnate Biopharma

Synopsis

  • Approved BRAF inhibitors such as vemurafenib, dabrafenib, and encorafenib are effective against cancers driven by V600 Class I mutations
  • BRAF Class II alterations (e.g. G469A or BRAF fusion) are RASindependent and RAF-dimer dependent and represent a molecular subtype in NSCLC with unmet need
  • BRAF Class III mutations represent a subtype with unmet need that are low kinase activity alterations that amplify upstream signaling from aberrant RTK (e.g. EGFR amplification) and/or RAS activation mechanisms
  • KIN-2787 is a clinical-stage pan-RAF inhibitor targeting dimer signaling in NSCLC patient populations while minimizing MAPK pathway paradoxical activation in normal wildtype signaling

11:30 am Speaker Q&A

11:35 am Targeting HER2 in NSCLC

12:05 pm Speaker Q&A

12:10 pm NRG1 Fusions: A Tumor-Agnostic Oncogenic Driver

  • Shawn Leland Founder & Chief Executive Officer , Elevation Oncology

Synopsis

  • Genomic alterations fall on a spectrum of oncogenic potential. “True” oncogenic driver alterations are optimal biomarkers for targeted therapy development in precision oncology
  • NRG1 fusions are emerging as “true” oncogenic driver alterations that can be found across solid tumor types and are enriched in certain NSCLC populations such as IMA
  • NRG1 fusions may be therapeutically actionable through inhibition of HER3 with mAbs such as seribantumab, currently being investigated in the Phase 2 tumor-agnostic CRESTONE trial

12:40 pm Speaker Q&A

12:45 pm Screen Break

Optimizing Precision Oncology, Treatment Regimes and Administration to Improve Patient Outlook

1:45 pm Towards Furthering Liquid Biopsy Use in Clinical Studies

  • Donald Johann Associate Professor - Medicine & Bioinformatics , University of Arkansas for Medical Sciences/ ATD LLC

Synopsis

– Sample collection & best practices
– Towards analytical validity – accuracy & reproducibility
– Approaches towards data harmonization

2:15 pm EGFR Exon 20 Insertions : A Complex Family of Mutations in NSCLC

Synopsis

  • Current testing methodologies to identify EGFR exon insertion
  • Companion Diagnostic planning to improve identification of patients with EGFR exon 20 insertion
  • Impact of EGFR exon 20 insertion variants on mobocertinib response

2:45 pm Title to be announced…

  • Partha M. Das Medical Director and US Medical Affairs Lead, Oncology Diagnostics and Biomarker Strategy , Amgen

3:15 pm BloodPAC Consortium: Accelerating Development, Approval & Accessibility

  • Lauren Leiman Executive Director , Blood Profiling Atlas in Cancer

3:45 pm Panel Discussion: Utilizing Precision Oncology for NSCLC Treatment

  • Donald Johann Associate Professor - Medicine & Bioinformatics , University of Arkansas for Medical Sciences/ ATD LLC
  • Sylvie Vincent Scientific Director , Takeda Oncology
  • Naveen Babbar Global Biomarker and Diagnostic Lead, Oncology Solid Tumors (Vice President) , Novartis
  • Lauren Leiman Executive Director , Blood Profiling Atlas in Cancer
  • Partha M. Das Medical Director and US Medical Affairs Lead, Oncology Diagnostics and Biomarker Strategy , Amgen

4:30 pm Virtual Speed Networking Afternoon Break

5:00 pm Panel Discussion: Predicting Future Directions for NSCLC Therapeutic Development and Treatment

  • Tony Jarkowski Executive Director, Early Development Program Lead, Bristol Myers- Squibb
  • Martha Neagu Associate Medical Director, AbbVie
  • Eric Murphy Co-Founder and Chief Scientific Officer , Kinnate Biopharma

Synopsis

  • How will future combinations, or novel therapeutic design (bispecifics etc), address acquired resistance to TKI treatments and improve patient outcomes?
  • How will new, fast and accurate diagnostic technologies enable appropriate patient selection for future clinical investigations and increase the clinical utility of new approved therapies?
  • What is on the horizon for targeted therapies for uncommon or previous undruggable mutations in NSCLC?
  • What are the next steps for immunotherapy in this space? What are the highly anticipated combination studies and emerging drug candidates on the horizon?
  • Is 2021 the year that checkpoint inhibitors break into the perioperative setting in NSCLC?

5:25 pm Closing Remarks from Chairperson

5:30 pm End of conference